In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American ...